VRXA logo

VERAXA BIOTECH HOLDING AG

VRXANASDAQ
🏆 #3765 by market capUS Equity
$1.32▼ $0.05 (−3.65%)
Market closed · at close
🔔
Track VRXA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.6%
7d▼ 5.7%
14d▼ 14.0%
30d▼ 2.2%
ytd▼ 87.5%
1y▼ 87.4%
🏦Market Cap
$187M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
80
Good

Trading Snapshot

Day Range
$1.31 – $1.34
52-Week Range
$1.27 – $27.36
Volume
$2.88B
Avg Volume
$3.19B
Shares Outstanding
141.4M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$15M
Last Q Revenue
$4M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—

Why Investors Own VRXA

  • ✓High-growth profile — revenue up +35.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 61% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VRXA logo

VERAXA BIOTECH HOLDING AG

VRXA
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$15M▲ +41.6% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.1%▲ +4.4% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$5M▲ +41.6% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2M▲ +41.6% YoY
StockOtter · stockotter.space

About VERAXA BIOTECH HOLDING AG

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$1.30
▼ −1.8% Downside
High Target$1.46
Low Target$1.20
Based on 22 analysts

Latest News & Updates

🚀
CNBC·2h ago

VERAXA BIOTECH HOLDING AG tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift VRXA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

VERAXA BIOTECH HOLDING AG announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.